Medindia

X

Eularis Analyzes Pre-Launch Brand Planning With New Pharmaceutical Industry Report

Tuesday, November 18, 2008 General News J E 4
Advertisement
NEW YORK, LONDON and TOKYO, Nov. 17 In today'senvironment, Pharmaceutical companies find themselves in a bind. Drug launchesused to be able to achieve high sales and profits -- until recently. EveryPharma company today is hoping to achieve their own immediate winners, thedrugs that are successful right from the start and provide years ofbusiness-sustaining profit. However, recent studies have shown that seven outof ten drugs launched in the last five years have failed to repay their R&Dinvestment.

Effective marketing and sales can literally mean billions during a drug'slaunch and during the lifetime value. A product's shaping, positioning, salesuptake and market performance, with proper marketing focus and support, cantranslate to the elusive blockbuster. The power is there... But how canmarketers deliver? More and more, companies are expecting marketers to beinstrumental at the key moment of launch, and marketers are under extremepressure. To deliver on the high hopes of Pharmaceutical brand launches,companies must engage in comprehensive pre-launch planning. But how can thisbe achieved effectively? Today, Eularis announces the availability of theirnew report, 'Pre-Launch Planning: Priming Your Pharmaceutical Brand for Profitand Success'.

In this report, we examine the concept and components of effectivepre-launch planning. We analyze the environment for Pharmaceuticals today. Wedescribe the phases of pre-launch planning and look at key organizationalstrategies, marketing tactics, regulatory considerations, and even globalissues. Finally, to help companies make tough decisions and engage ineffective planning, we examine powerful pre-launch analytics techniques andcase studies of success. Written for CEO's, Marketing Executives and SalesExecutives, this report uncovers the factors that are effective for a highlysuccessful launch -- and the barriers against it -- offering secrets to getthe most out of your launch.

"Although the Pharmaceutical Industry has already widely-adoptedpre-launch market research, analysis and analytics into many product launchstrategies," said the author of the report, Dr. Andree K. Bates, President ofEularis, "we are starting to see that the approaches taken in the past areinsufficient in today's turbulent environment, and companies need to carefullyconsider exactly what kind of analysis is required now to mount a hugelysuccessful launch."

Dr. Bates has gained wide recognition within the internationalPharmaceutical Industry for her expertise in Pharmaceutical MarketingAnalysis. In addition to this and other must-have reports for PharmaceuticalIndustry marketers, she has authored many articles in peer-reviewed journalsand several chapters in books on Pharmaceutical Analytics.

To purchase the Eularis report, "Pre-Launch Planning: Priming YourPharmaceutical Brand for Profit and Success", visit:http://www.pharmaprelaunchroi.com/index.asp or, for more information aboutEularis, visit http://www.eularis.com.

ABOUT EULARIS

Eularis provides sophisticated Pharmaceutical analytics that providedata-driven insight into the financial impact of corporate and marketingdecisions. Unlike traditional analytics approaches, which are lengthy andwhose reliance on historical or analogue data reduces their accuracy, Eularis'proprietary 94.8 Analytics Process is based on the current market situation.This proven approach helps Pharmaceutical marketing teams to quickly plan,measure, validate and optimize their sales and marketing performance. Eularisoffers pre-launch analytics, marketing mix modeling (both professional andconsumer), portfolio optimization, sales force effectiveness, Managed Careanalytics, patient compliance solutions and Generics defense analysisstrategies. With offices in London, New York and Tokyo, the company hasdeveloped significant experience in the global Pharmaceutical market throughclient engagements with AstraZeneca, GlaxoSmithKline, Merck, Pfizer and manyothers. More information: http://www.eularis.com.

*(LOGO: Send2Press.com/mediaboom/08-0630-Eularis_72dpi.jpg)

This release was issued on behalf of the above organization bySend2Press(R), a unit of Neotrope(R). http://www.Send2Press.com

SOURCE Eularis
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Cord Blood America Positioning for Excellent 2009 ...
S
Virginia HMO Quality Usually Better than Nation, a...